Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Flowscape receives large room panel order from international corporate customer

In conjunction with an ongoing global rollout of the Flowscape system for an international corporate customer, Flowscape has received a large order for room panels worth SEK 2 million.The order is part of a major framework agreement between the international corporate customer and Flowscape, where the Flowscape system is rolled out at the customer's various international offices in several stages. The previous order, which was announced on January 25, 2019, concerned software. In this stage, hardware in the form of room panels has been ordered in an order worth SEK 2 million. In

Keliber updated DFS: Lithium hydroxide production significantly improves profitability

Keliber Oy’s Definitive Feasibility Study (“DFS”) for the lithium hydroxide production shows a significant improvement in profitability compared to previous assessments. The updated DFS shows a pre-tax NPV (8% discount rate) of EUR 510m, pre-tax IRR of 28% and a payback period of 3.7 years.Keliber Oy (“Keliber”) published the DFS for the Lithium Project (“the Project”) during summer 2018 based on the production of battery-grade lithium carbonate. However, Keliber estimated that lithium demand, especially from the cathode chemical, lithium-ion battery and electric vehicle manufacturers in

Updated Definitive Feasibility Study: Lithium hydroxide production significantly improves profitability of Keliber’s Lithium Project

The economic calculations of Keliber Oy’s Definitive Feasibility Study for the lithium hydroxide production show a significant improvement in profitability.Keliber Oy’s (“Keliber” or “the Company”) updated Definitive Feasibility Study for the lithium hydroxide production (“updated Definitive Feasibility Study” or “updated DFS”) confirms Lithium Project’s (“the Project”) strong financial and technical feasibility. All the key financial figures have improved significantly compared to the Definitive Feasibility Study based on lithium carbonate production (“DFS”) published in summer 2018.

Interim report January - December 2018

October - December · Net sales for the period increased with 19.4% to EUR 57.1 (47.8) million due to the acquisition of Sataservice from August 2018, partly offset by unfavorable currency effects and loss of a few contracts. Net sales declined organically with 1.9% compared to prior year · During the quarter three contracts were won, eight contracts were lost, and four contracts were renewed, which on balance affected the contract portfolio negatively. Portfolio run rate annualized net sales at the end of the quarter was EUR 205.5 (187.8) million · Operating loss improved to EUR -

Basware announces termination of discussions with Tradeshift Holdings Inc

Basware Corporation, stock exchange release, February 28, 2019 at 09:45 a.m. EETBasware Board of Directors today announces that is has terminated discussions with Tradeshift Holdings Inc (“Tradeshift”). In announcements in November and December 2018, Basware confirmed that it was in discussions with Tradeshift in relation to a possible cash tender offer by Tradeshift for all shares in Basware (the “Possible Offer”). Tradeshift has recently informed Basware that it will be unable to proceed given conditions in the capital markets. On this basis, the Board of Directors of Basware has

Year-end Report 2018

JANUARY–DECEMBER 2018 (COMPARED WITH JANUARY–DECEMBER 2017) ·Revenue increased by 42% to SEK 435.8 million (307.5) ·Net interest income increased by 46% to SEK 357.1 million (243.8) ·Adjusted Earnings before tax increased by 27% to SEK 152.2 million (119.5) ·Cost/income ratio decreased to 0.31 (0.32) ·The return on equity was 39% THE FOURTH QUARTER (COMPARED WITH THE FOURTH QUARTER OF 2017) ·Revenue increased by 6% to SEK 103.0 million (97.0) ·Net interest income increased by 10% to SEK 85.3 million (77.8) ·Earnings before tax

EAB Group Plc, Company Announcement, 28 February 2019, 9:30 a.m. (EET)

EAB Group Plc, Company Announcement, 28 February 2019, 9:30 a.m. (EET) Notice to the annual general meeting of EAB Group Plc EAB Group Plc's shareholders are invited to the Annual Meeting to be held on Friday 5 April 2019 at 09.30 EET at the Rake-Sali Ball Room, at Erottajankatu 4 C, Helsinki. The reception of participants enrolled to the meeting will begin at 08.30 EET. ITEMS ON THE AGENDA OF THE ANNUAL GENERAL MEETING 1. Opening of the meeting  2. Calling the meeting to order  3. Election of persons to scrutinise the minutes and to supervise the counting of votes

Interim Report January – December 2018

During the quarter we saw a more stable Swedish krona which reduced the negative currency effect on our earnings experienced previously. Also, we have seen positive effects from the previously announced program to increase profitability. Most of the activities to increase margins on products with low profitability have been implemented and we observed a positive trend in our profit levels compared to earlier quarters. The ongoing investment projects for the passenger car business went according to plan during the quarter and these investments continue also during the coming quarters. We

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 71,661,048 as a result of a partial registration of the preferential rights issue, resolved by the Board of Directors on 10 December 2018 and approved at the Extraordinary General Meeting on 17 January 2019.Today, the last trading day of the month, there are in total 163,358,124 shares and votes in NeuroVive Pharmaceutical AB.  This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to

NeuroVive Pharmaceutical AB Year End Report January - December 2018

Positioned for clinical progressImportant events January-December 2018 Quarter 1 · Positive experimental efficacy data for NVP025. · Decision on a rights issue (extraordinary general meeting). Quarter 2 · NeuroVive and Yungjin reports positive KL1333 phase I clinical study results. · KL1333 receives FDA Orphan Drug Designation for treatment of mitochondrial diseases. · Positive efficacy data in an experimental model, entailing a breakthrough for the NVP025 mitochondrial myopathy project. · NeuroVive initiates collaboration with leading US TBI research

Year-End Report 2018

Continue increase order intake and more customers Fourth quarter of 2018 · Net sales for the period amounted to SEK 6.8 (0.8) million and earnings to SEK -22.9 (-19.9) million, which corresponds to earnings per share of SEK -0.53 (-0.86). · Cash and cash equivalents on December 31 amounted to SEK 7.5 million. · A new order of SEK 4.5 million was received in December for Ångströmlaboratoriet in Uppsala. · After the acquisition the assets of I-Window International AB were acquired to broaden the product portfolio and strengthen the sales organization we see a positive

Year-end report 2018

Intensified work with ChloraSolv.JANUARY−DECEMBER 2018 ·Net sales amounted to SEK 2.6 million (2.3), a revenue growth of 12.1 percent. ·Earnings before interest and taxes (EBIT) amounted to SEK -21.9 million (-19.3). ·Earnings per share after dilution at SEK -0.36 (-0.34). ·Cash flow from operating activities amounted to SEK -21.7 million (-15.9). ·Cash flow from financing activities amounted to SEK +2.5 million (63.0). ·Liquid assets at the end of the period at SEK 22.6 million (44.9). · Equity ratio was 84 percent (88).  OCTOBER−DECEMBER

GomSpace (provider of nanosatellites) announces its quarterly results for the fourth quarter 2018

Stockholm, February 28, 2019. GomSpace Group AB (the “Company”) announces its interim report for the fourth quarter of 2018. The report is available on the Company’s homepage (www.gomspace.com). The following is taken from the quarterly report: “The net revenue in 2018 amounted to T.SEK 153,384 com­pared to T.SEK 96,405 in 2017. This corresponds to a growth rate of 59%. Without the impact of the elimination of sales to associated companies, the growth rate corresponds to 63%. The gross margin amounts to 25%; without elimination, it would have been 30%. We did not fully reach the

Nuevolution-Almirall Partnership Achieves First Collaboration Milestone for Dermatology Diseases

Stockholm, 28 February 2019. Nuevolution AB (publ) (NUE.ST) announced today that a key milestone under the collaboration with Almirall has been achieved. The strategic collaboration was entered on December 12, 2016 with the aim to develop innovative RORγt inhibitors with best-in-class potential for the oral and topical treatment of Dermatology diseases and Psoriatic Arthritis. A significant part of the collaboration work has been to evaluate preclinical safety parameters of RORγt inhibition and to comprehensively de-risk the program prior to any human testing. The milestone data

Smart Eye names two additional car models

Today Smart Eye is able to name two additional car models from BMW: BMW X3 and X4.Smart Eye’s DMS technology will aid gaining insights into the driver’s attention state, focus and drowsiness on the road, understanding and assisting the driver in necessary situations. Fulfilling the criteria of the new EU car safety agenda and approved proposal. Smart Eye is proud to be an entrusted partner for the future generation of semi-autonomous cars together with the BMW Group, paving the way for a high-quality and safe drive. BMW X3 and BMW X4 are two of the 43 design-wins Smart Eye currently

Year end report Scandinavian Enviro Systems AB (publ) January – December 2018

Rights issue adds capital of MSEK 84.5 N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.Q4 2018 ·  Net revenues for the period were MSEK 0.3 (0.3)  ·  Earnings after tax for the period were MSEK -10.8 (-8.2)   ·  Earnings per share for the period (before dilution) was SEK -0.08 (-0.07)   ·  Cash flow for the period after investments was MSEK -6.1 (-4.8)  ·  Signing of MoU with EE-TDF Cleveland LLC regarding a plant in Texas, USA  ·

Notice to Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)

The shareholders of ExpreS2ion Biotech Holding AB, 559033-3729, are hereby invited to attend an Extraordinary General Meeting on Tuesday, March 19, 2019, at 10.00 at c/o Mazars SET, Terminalgatan 1, in Helsingborg.Right to participate and registration Shareholders who wish to attend the General Meeting shall · be entered in the share register on Wednesday the 13th of March 2019, and · sign up to the Company no later than Wednesday the 13th of March 2019 in writing to ExpreS2ion Biotech Holding AB, att: Extraordinary General Meeting, c/o Mazars SET, Terminalgatan 1, 252 78

Borr Drilling Limited (BDRILL) Announces Preliminary Results for the Fourth Quarter and Year Ended 2018

Hamilton, Bermuda, February 28, 2019: Borr Drilling Limited (“Borr” or the “Company”) announces preliminary results for the three and twelve months ended December 31, 2018 Highlights in the fourth quarter 2018 ·  Operating revenues of US$53.5 million, EBITDA of negative US$18.7 million and net loss of US$110.7 million for the fourth quarter of 2018 ·  Operating revenues of US$164.9 million, EBITDA of negative US$65.8 million and net loss of US$190.9 million for the year ended December 31, 2018 ·  Technical utilisation for the operating rigs was 99.6% in the fourth quarter of

ExpreS2ion conducts a directed share issue to accelerate the development of the company

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that the Company is conducting a directed share issue to a number of existing shareholders and strategic investors of initially approx. SEK 8 million, with attached consideration-free warrants, which in later stages can provide the Company with a further approx. SEK 9.6 million. The directed share issue is conducted in order to finance an accelerated pace of operations and increased investments in the business to ensure long-term good development. The motive to deviate from the shareholders' preferential rights is that considers it

EAB Group Plc's financial statements bulletin for 2018 - Group's comparable net turnover** grew 23% and AuM 8%

EAB Group Plc, Company Announcement, 28 February 2019, 9:00 a.m. (EET) EAB Group Plc's financial statements bulletin for 2018 - Group's comparable net turnover** grew 23% and AuM 8% EAB Group's (hereinafter EAB or Group) IFRS turnover during 1 January-31 December 2018 period amounted to EUR 19.6 million (EUR 17.6 million in 2017) and profit for the financial year amounted to EUR 1.4 million (-EUR 2.3 million). The Group's operating profit was EUR 1.8 million (-EUR 2.6 million in 2017). Turnover comprised fee income from fund management amounting to EUR 12.5 million (EUR 9.4 million),

ExpreS2ion Biotech Holding AB: Publication of financial report for January – December 2018

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report for the period of January – December 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.CEO Dr. Steen Klysner comments “In 2018 we focused on the continued expansion of our core platform by developing and including new technologies, as well as strengthening our joint venture AdaptVac. We have succeeded well with these activities and have documented good progress in a number of existing and new

Year End Report 2018 Azelio AB

2018 was a positive and eventful year for Azelio. The demonstration of the Company’s proprietary energy storage technology attracted attention from around the world, resulting in enquiries from potential customers in over 50 countries. The Company’s development and industrialization is continuing according to plan towards a full-scale verification project later this year, smaller commercial projects next year followed by a ramp up in volumes. In the fourth quarter Azelio was listed on Nasdaq First North. With the listing, the company brought in 242 million SEK before transaction costs and 2,

Increased numbers of shares and votes in Catena Media plc

The number of shares and votes in Catena Media plc amounts to 56,777,004 shares and votes following a directed share issue of 468,132 shares.Catena Media has, as announced on 13 February 2019 , resolved on a directed share issue of 468,132 shares as payment of part of the upfront purchase price for acquired assets in Baybets Ltd. The share issue has been registered with Maltese authorities in February 2019. Subsequent to the share issue, the

DOME ENERGY PRESENTS INTERIM REPORT FOR JULY-DECEMBER 2018

SECOND HALF-YEAR · Revenue from oil & gas production incl. realized derivatives $5,015’ (4,245’). · Effect from unrealized derivatives of $1 947’ (-338). · Gross result from production incl. realized derivatives $2,710’ (1,511’) with a margin of 54% (36%). · EBITDA of $1,405’ (-839’). · EBITDA for US operations adj. for unrealized derivatives amounted -$5’ (- 9’). · Net result of -$11,840’ (20,543’). · Earnings per share -$1.60 (4.38). FULL YEAR · Revenue from oil & gas production incl. realized derivatives $9,639’ (7,952’). · Effect from unrealized

There are no items matching the current filter
There are no more items matching the current filter
Back to top